Denali Therapeutics (DNLI) Operating Leases (2019 - 2026)

Denali Therapeutics (DNLI) has reported Operating Leases for 8 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 42.65% year-over-year to $24.7 million; the TTM figure through Mar 2026 stood at $24.7 million (down 42.65% YoY), while the FY2025 annual figure was $27.2 million, down 25.8% from the prior year.
• Operating Leases retreated to $24.7 million in Q1 2026 per DNLI's latest filing, from $27.2 million in the prior quarter.
• Across five years, Operating Leases topped out at $62.0 million in Q3 2022 and bottomed at $24.7 million in Q1 2026.
• Historically, Operating Leases has averaged $45.4 million across 5 years, with a median of $46.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases rose 3.43% — and 2026, when it tumbled 42.65%.
• Denali Therapeutics' Operating Leases stood at $53.0 million in 2022, then retreated by 15.18% to $45.0 million in 2023, then decreased by 18.47% to $36.7 million in 2024, then dropped by 25.8% to $27.2 million in 2025, then dropped by 9.3% to $24.7 million in 2026.
• Business Quant data shows DNLI's Operating Leases at $24.7 million in Q1 2026, $27.2 million in Q4 2025, and $29.7 million in Q3 2025.